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Executive summary
50 years after a noble but flawed attempt to eradicate 
malaria in the mid-20th century, the global malaria 
community is once again seriously considering eradi-
cation. Momentum towards eradication has been 
building for decades, and more than half of the world’s 
countries are now malaria free. Since 2000, a surge of 
global progress has occurred, facilitated by the roll-out of 
new technologies and the substantial growth in political 
and financial commitment by countries, regions, and 
their global partners. Annual domestic and inter-
national spending on malaria increased from roughly 
US$1·5 billion in 2000 to $4·3 billion in 2016. 
Simultaneously, the number of countries with endemic 
malaria dropped from 106 to 86, the worldwide annual 
incidence rate of malaria declined by 36%, and the 
annual death rate declined by 60%.
Inspired by these outstanding achievements, and 
troubled by a stagnation in progress that saw 55 countries 
report an increase in cases between 2015 and 2017, 
the Lancet Commission on Malaria Eradication (the 
Commission) was convened to consider whether malaria 
eradication is feasible, affordable, and worthwhile. In 
this report of the Commission, we synthesise existing 
evidence and new epidemiological and financial analyses 
to show that malaria eradication by 2050 is a bold but 
attainable goal, and a necessary one given the never-
ending struggle against drug and insecticide resistance 
and the social and economic costs associated with a 
failure to eradicate.
Global social, economic, and environmental trends 
are, in most places, reducing malaria. Our models show 
that these trends alone will lead to greatly reduced but 
still widespread malaria by 2050. When the effects of 
enhanced access to high-quality diagnosis, treatment, 
and vector control are factored in, the 2050 projections 
show a world largely free of malaria, but with pockets of 
low-level transmission persisting in a belt across Africa, 
from Senegal in the northwest to Mozambique in the 
southeast. In view of these projections, we explore the 
responses to the operational, biological, and financial 
challenges that are required to bend the curve (ie, to 
accelerate the decline in malaria cases and deaths) and 
achieve elimination everywhere outside of Africa by 2030 
and worldwide eradication by 2050.
Operational obstacles limit the success of malaria 
programmes in many countries, including ineffective 
management, inadequate use of data to inform strategies, 
poorly incentivised staff, and disengaged communities. 
Solutions to most of these challenges are available and 
inexpensive but require access to management training 
and tools, which many malaria programmes do not have. 
Strengthening programme management and improving 
the availability and use of data for decision making are 
operational priorities which, if addressed, would enhance 
programme effectiveness and accelerate the path to 
malaria eradication. Leveraging the expertise and com-
parative advantages of the private sector and forming 
close partnerships with private health-care providers will 
further strengthen performance.
Multiple challenges arise from the complexity of malaria 
biology: malaria parasites and their mosquito vectors are 
constantly evolving resistance to widely used drugs and 
insecticides, the most common methods of parasite 
detection are not sensitive enough to identify all infections, 
simian malaria is now common in humans in parts of 
southeast Asia, and the effectiveness of standard vector 
control interventions is low in areas with the highest 
transmission intensity and where outdoor biting is 
common. Encouragingly, the research and develop ment 
pipeline for drugs, insecticides, diagnostics, and vector 
control tools is robust. Promising new products with 
strong potential to overcome existing challenges have 
become available in the past 5 years or are scheduled to roll 
